Semax

This in vivo study in male Wistar rats characterized the time-course of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) gene expression in three central nervous system regions — hippocampus, frontal cortex, and retina — at 20 min, 40 min, 90 min, 3 h, 8 h, and 24 h after Semax administration. Expression levels were quantified by real-time PCR. The authors reported multidirectional, region- and time-dependent modulation of both neurotrophin genes: a transient decrease in hippocampal and retinal NGF/BDNF mRNA at 20 min, an increase in frontal cortex at the same early time point, and a significant rise in retinal BDNF expression by 90 min. These data were interpreted as evidence that Semax engages the neurotrophin system through coordinated regional transcriptional dynamics rather than a single uniform upregulation.

Researchers gave Semax to rats and measured the activity of two genes — NGF and BDNF — that produce proteins which help brain cells survive and form new connections. They looked at three brain-related regions (the memory center, the front of the brain, and the retina) at several time points. They found that Semax did not simply turn these genes "up" everywhere — instead, it shifted their activity in different directions in different regions at different times. The pattern is consistent with Semax acting as a regional signal that retunes neurotrophin production rather than a blanket booster.

This rodent study examined Semax's effect on central monoaminergic systems. Using microdialysis and tissue measurements, the authors reported that Semax administration was associated with positive modulation of the striatal serotonergic system and an enhanced striatal release of dopamine, as well as potentiation of locomotor behavior elicited by D-amphetamine. The findings linked Semax's previously documented nootropic profile to measurable changes in dopaminergic and serotonergic neurotransmission, providing a mechanistic bridge between the peptide's structural derivation from ACTH(4-10) and its observed behavioral effects in rodent models.

Scientists looked at what Semax does to two of the brain's main chemical messenger systems — dopamine and serotonin — in rats and mice. They found that Semax increased the release of dopamine in a brain region called the striatum and boosted serotonin signaling there as well. When they gave the animals amphetamine (which itself increases dopamine), Semax made the movement-related response stronger. This suggests Semax doesn't act on a single isolated target — it tunes several of the brain's chemical signaling systems at once.